IL317679A - Methods for treatment of previously untreated follicular lymphoma with mosunetuzumab and lenalidomide - Google Patents
Methods for treatment of previously untreated follicular lymphoma with mosunetuzumab and lenalidomideInfo
- Publication number
- IL317679A IL317679A IL317679A IL31767924A IL317679A IL 317679 A IL317679 A IL 317679A IL 317679 A IL317679 A IL 317679A IL 31767924 A IL31767924 A IL 31767924A IL 317679 A IL317679 A IL 317679A
- Authority
- IL
- Israel
- Prior art keywords
- dose
- mosunetuzumab
- administered
- dosing cycle
- rasburicase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Claims (1)
1. PATENT Attorney Docket No.: 50474-298WOGenentech Docket No.: P37627-WO 48. The method of any one of claims 44-47, wherein the prophylactic agent against TLS comprises allopurinol. 49. The method of claim 48, wherein the initial dose of allopurinol is administered about 72 hours prior to the administration of any dose of mosunetuzumab. 50. The method of claim 49, wherein additional single doses of allopurinol are administered daily for 6-10 days after the administration of the initial dose. 51. The method of any one of claims 48-50, wherein the initial dose of allopurinol is about 3mg. 52. The method of claim 50 or 51, wherein each additional single dose of allopurinol is about 3mg. 53. The method of any one of claims 48-52, wherein allopurinol is administered orally. 54. The method of any one of claims 44-47, wherein the prophylactic agent against TLS comprises rasburicase. 55. The method of claim 54, wherein the initial dose of rasburicase is administered about minutes prior to the administration of any dose of mosunetuzumab. 56. The method of claim 55, wherein additional single doses of rasburicase are administered daily for 1-5 days after the administration of the initial dose. 57. The method of any one of claims 54-56, wherein the initial dose of rasburicase is about 0.mg/kg. 58. The method of claim 56 or 57, wherein each additional single dose of rasburicase is about 0.2 mg/kg. 59. The method of any one of claims 54-58, wherein rasburicase is administered intravenously. 60. Mosunetuzumab and lenalidomide for use in a method of treating a subject having a previously untreated follicular lymphoma (FL), wherein the method comprises administering to the subject the mosunetuzumab and the lenalidomide according to a dosing regimen comprising a first 21-day dosing cycle and a second 28-day dosing cycle, wherein: (a) the first dosing cycle comprises a first dose (C1D1), a second dose (C1D2), and a third dose (C1D3) of mosunetuzumab subcutaneously administered on Days 1, 8, and 15, PATENT Attorney Docket No.: 50474-298WOGenentech Docket No.: P37627-WO respectively, of the first dosing cycle, wherein the C1D1 is about 5 mg, the C1D2 is about 45 mg, and the C1D3 is about 45 mg, (b) the second dosing cycle comprises a single dose (C2D1) of mosunetuzumab subcutaneously administered on Day 1 of the second dosing cycle, wherein the C2D1 is about mg, and (c) the second dosing cycle further comprises orally administering between about mg and about 20 mg lenalidomide daily on Days 1-21 of the second dosing cycle.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263354491P | 2022-06-22 | 2022-06-22 | |
| PCT/US2023/068804 WO2023250367A1 (en) | 2022-06-22 | 2023-06-21 | Methods for treatment of previously untreated follicular lymphoma with mosunetuzumab and lenalidomide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL317679A true IL317679A (en) | 2025-02-01 |
Family
ID=87519897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL317679A IL317679A (en) | 2022-06-22 | 2023-06-21 | Methods for treatment of previously untreated follicular lymphoma with mosunetuzumab and lenalidomide |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240043553A1 (en) |
| EP (1) | EP4543546A1 (en) |
| JP (1) | JP2025521501A (en) |
| KR (1) | KR20250025678A (en) |
| CN (1) | CN119546334A (en) |
| AU (1) | AU2023286618A1 (en) |
| CA (1) | CA3259327A1 (en) |
| IL (1) | IL317679A (en) |
| MX (1) | MX2024015750A (en) |
| TW (1) | TWI881370B (en) |
| WO (1) | WO2023250367A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026006456A1 (en) * | 2024-06-25 | 2026-01-02 | Genentech, Inc. | Methods of treating cancer using subcutaneous dosing of mosunetuzumab as a monotherapy or in combination with lenalidomide |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
| IL301086A (en) * | 2020-09-10 | 2023-05-01 | Genmab As | Bispecific antibody against CD3 and CD20 in combination therapy for the treatment of follicular lymphoma |
| WO2022098638A2 (en) * | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| JP7716473B2 (en) * | 2020-11-04 | 2025-07-31 | ジェネンテック, インコーポレイテッド | Subcutaneous administration of anti-CD20/anti-CD3 bispecific antibodies |
| WO2026006456A1 (en) * | 2024-06-25 | 2026-01-02 | Genentech, Inc. | Methods of treating cancer using subcutaneous dosing of mosunetuzumab as a monotherapy or in combination with lenalidomide |
-
2023
- 2023-06-21 CA CA3259327A patent/CA3259327A1/en active Pending
- 2023-06-21 IL IL317679A patent/IL317679A/en unknown
- 2023-06-21 WO PCT/US2023/068804 patent/WO2023250367A1/en not_active Ceased
- 2023-06-21 TW TW112123338A patent/TWI881370B/en active
- 2023-06-21 US US18/338,985 patent/US20240043553A1/en active Pending
- 2023-06-21 CN CN202380047723.4A patent/CN119546334A/en active Pending
- 2023-06-21 KR KR1020257000914A patent/KR20250025678A/en active Pending
- 2023-06-21 AU AU2023286618A patent/AU2023286618A1/en active Pending
- 2023-06-21 JP JP2024574565A patent/JP2025521501A/en active Pending
- 2023-06-21 EP EP23748657.6A patent/EP4543546A1/en active Pending
-
2024
- 2024-12-17 MX MX2024015750A patent/MX2024015750A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025521501A (en) | 2025-07-10 |
| TWI881370B (en) | 2025-04-21 |
| CA3259327A1 (en) | 2023-12-28 |
| MX2024015750A (en) | 2025-02-10 |
| WO2023250367A1 (en) | 2023-12-28 |
| CN119546334A (en) | 2025-02-28 |
| KR20250025678A (en) | 2025-02-24 |
| EP4543546A1 (en) | 2025-04-30 |
| TW202409075A (en) | 2024-03-01 |
| US20240043553A1 (en) | 2024-02-08 |
| AU2023286618A1 (en) | 2025-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Büchner et al. | Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. | |
| Gottlieb et al. | Chemotherapy of malignant lymphoma with adriamycin | |
| Rowinsky | Update on the antitumor activity of paclitaxel in clinical trials | |
| JP2022549621A5 (en) | ||
| Ferrara et al. | Vincristine as salvage treatment for refractory thrombotic thrombocytopenic purpura | |
| JPS62145029A (en) | Interferon composition | |
| Frakes et al. | An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant | |
| JP2025521501A5 (en) | ||
| WO1995024927A1 (en) | Immunotherapeutic method of treating cancerous diseases by administration of gamma globulins | |
| Gottlieb et al. | Whether or not to Administer Amphotericin to an Immunosuppressed Patient with Hematologic Malignancy and Undiagnosed Fevert | |
| US5756514A (en) | Methods for treatment and prevention of drug-induced pruritus with serotonin type 3 receptor antagonists | |
| Adamczyk et al. | A 12-year old girl with severe plaque psoriasis and Down syndrome treated successfuly with etanercept | |
| Cersosimo et al. | Acute hypotensive reaction to etoposide with successful rechallenge: case report and review of the literature | |
| Suzuki et al. | Primary plasma cell leukemia: a case report of successful responder to a combination chemotherapy of vincristine, doxorubicin and dexamethasone | |
| RU2024139114A (en) | TREATMENT OF PREVIOUSLY UNTREATABLE FOLLICULAR LYMPHOMA WITH MOSUNETUZUMAB AND LENALIDOMIDE | |
| Petrova et al. | Efficacy and safety of SGLT2 inhibitors in patients with type 2 diabetes mellitus: a systematic review | |
| Sanborn et al. | Efficacy of dacarbazine (DTIC) in preventing metastases arising from intraocular melanomas in mice | |
| Avanzini et al. | INSIGHT and NORDIL | |
| Gorschlüter et al. | Successful induction and consolidation therapy of acute myeloid leukaemia in a renal allograft recipient. | |
| US5571800A (en) | Method for inhibiting allograft rejection by the administration of 6-azauridine or its triacetate derivative | |
| Roila et al. | Antiemetic activity of two different high doses and schedules of metoclopramide in dacarbazine-treated cancer patients | |
| Sleight | Surival following thrombolytic therapy | |
| JPH0251405B2 (en) | ||
| Bazzoli et al. | Efficacy of omeprazole plus amoxicillin or amoxicillin plus clarithromyicin for 1 week or 2 weeks for Hericobacter pylori eradication in patients with duodenal ulcer | |
| Doyle | Long-Term Data Support Use of Acalabrutinib in Treatment-Naïve Patients with Chronic Lymphocytic Leukemia. |